Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104 th American Association for Thoracic Surgery (AATS) Annual Meeting in Toronto, Canada Presentations highlighted 5-year real-world safety and efficacy data from the On-X Aortic Heart Valve Low INR post-market study that demonstrate even better patient outcomes than predicted by the On-X Aortic Heart Valve PROACT IDE Study, as well as Late-Breaking data from the AMDS PERSEVERE Trial demonstrating, at 30-days post-AMDS implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry (DANE) tears. 5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low IN
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? [Yahoo! Finance]Yahoo! Finance
- Shareholders Will Probably Hold Off On Increasing Artivion, Inc.'s (NYSE:AORT) CEO Compensation For The Time Being [Yahoo! Finance]Yahoo! Finance
- Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Stifel Nicolaus from $22.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Needham & Company LLC from $25.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
AORT
Earnings
- 5/6/24 - Beat
AORT
Sec Filings
- 5/13/24 - Form 4
- 5/10/24 - Form 144
- 5/10/24 - Form 4
- AORT's page on the SEC website